TMRW
Tmrw, a new and scalable Learning Operating System (LearnOS) for global education with a mission to help bring a quality education to every child, was launched this month.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211207005768/en/
Its interoperable All-In-One Integrated Platform is built to be accessible and affordable for Government funded schools operating in both the developed and developing world settings. In particular, it seeks to reach all students irrespective of their background or their ability to pay. It is designed to cater to the needs of every curriculum, context and mode of learning, whether brick and mortar, virtual or blended. Tmrw’s vision over time is to underpin learning, teaching, and the operational needs of K12 education, higher education and life-long learning.
Sunny Varkey, who also founded the Global Teacher Prize, has ensured that Tmrw has been teacher-led from the drawing board to its final roll-out. Uniquely, he has been able to draw upon the teaching talent within the GEMS schools network, which includes 20,000 inspired and qualified teachers, teaching support staff and school administrators from all nationalities, delivering seven different curricula in 16 countries.
The ongoing COVID-19 pandemic has emphasised the urgent need for an integrated technological solution for global education that can streamline end-to-end processes and utilise data to improve teaching and learning, while providing a seamless experience for all. Tmrw seeks to fill this void by providing an education eco-system that offers far more than a traditional, stand-alone learning or school management system. Working in collaboration with schools and teachers, our ambition is that Tmrw becomes an accepted LearnOS of global education – giving every learner an opportunity to participate in the future.
Tmrw’s EdTech platform includes a comprehensive suite of modules that can be introduced as a full ecosystem or as bolt-ons that are interoperable with technologies from other providers, offering schools the efficiency gains that integration can bring.
The platform includes modules to manage and oversee the curriculum, assessment, and track student progress. It has non-academic functionalities such as sports management, counselling and well-being. It allows schools to manage parent and student relations and includes custom-built health and child safety guarding features. It also includes back-office operations such as revenue management, HR, payroll, finance and procurement.
Tmrw is not just a technology company, but an education transformation company that offers comprehensive educational services such as:
- Tmrw Academy – focused on professional development including teacher training
- Education Command Center – serving policy makers with real-time decision-making capabilities at a national level
- Tech-In-A-Box – Comprehensive technology backbone covering the school eco system end to end.
- Tmrw Advisory Services for educational institutions on curriculum design, digital transformation, school improvement and nation-wide educational strategies.
Spun out from GEMS Education, Tmrw has been incorporated as the independent technology entity of GEMS and so will draw on the experience of the largest private K-12 education provider in the world, where its solutions have proven themselves to be scalable and effective with real students in a real classroom environment. GEMS Education, since it was founded 62 years ago, has provided a quality and values driven education throughout the world.
During the pandemic, GEMS Education moved seamlessly online from the start of the crisis because for the last decade it has built, tested, and constantly improved an education platform with real teachers and real students in real classrooms. This culture of improvement, driven both by analytics and constant engagement with the experience of teachers and partners, will be at the heart of Tmrw.
Today, GEMS is the only private-sector education operator with an all-inclusive platform for teachers, pupils, and parents. That experience is the foundation of Tmrw, which seeks to create an impact on a billion learners through technology, backed by a team that has touched millions of lives over decades.
Mr. Sunny Varkey, Chairman and Founder of Tmrw and GEMS Education, said:
“Quality education is the great equaliser. It bridges the gap between the rich and the poor and gives us the greatest opportunity to improve the state of our world.
“We have built this platform to be accessible and affordable for Government funded schools throughout the world to help improve learning outcomes wherever we can. We seek to reach all students irrespective of their background or their ability to pay. Ultimately, our vision is to give every child their birth-right of a great education and provide hope for a better future.
“We can only achieve this mission if we learn lessons from the frontline of education. For far too long edtech has side-lined the voice of the teacher. Not this time, as teachers will be the beating heart of Tmrw. They will be our designers, our content creators and our toughest critics.”
Tmrw CEO and GEMS Education Group Chief Disruption Officer, Mr Krishnan Gopi, said:
“Education is transforming at pace, moving away from the conventional patterns of teaching and learning that have dominated the sector. There is an undeniable, growing awareness among educators and families that education must evolve to meet tomorrow’s reality.
“Designed by educators for educators, Tmrw will help students learn better, teachers teach better, parents become more engaged, and schools become more efficient”.
Our platform is secure, scalable, multi-lingual and highly configurable to meet different needs of education systems across the globe. It utilizes exponential technologies such as AI / ML, AR /VR, Blockchain and IOT to revolutionise the teaching and learning experience.
*For more information about how Tmrw can empower schools to deliver enhanced teaching and learning outcomes please email: info@tmrw.group
View source version on businesswire.com: https://www.businesswire.com/news/home/20211207005768/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release
Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom